Full Press Release Details
Pharmaceuticals Appoints Mr. Lynn Swann, Pro-Football Hall of Famer, ABC
Broadcaster, and Former Chairman of the President's Council on Physical Fitness
and Sports, to Board of Directors
Business, Media, and Community Leader To Contribute To Specialty Pharma's
Corporate Governance
CA - November 24, 2008 -- Transdel Pharmaceuticals, Inc. (OTC BB:TDLP), a
specialty pharmaceutical company focused on the development and
commercialization of non-invasive topically targeted medications, today
announced that Mr. Lynn Swann has been appointed to the Company's Board of
president of Swann, Inc., a consulting firm specializing in marketing and
communications and managing director of Diamond Edge Capital Partners, LLC,
New York-based finance company.
currently serves on the Board of Directors of H.J. Heinz Company, Hershey
Entertainment and Resorts Company and Harrah's Entertainment, Inc. He was also
chairman of the President's Council on Physical Fitness and Sports from
2002-2005. A former all-pro wide receiver for the Pittsburgh Steelers and
Hall of Famer, he spent twenty-nine years with ABC Sports as a sports analyst
and broadcaster before retiring in 2006.
community affairs, Mr. Swann is national spokesman and former board president
Big Brothers and Sisters of America and former director of the Pittsburgh
Theatre. Mr. Swann holds a B.A. degree in public relations from the University
of Southern California.
Juliet Singh, President and CEO of Transdel Pharmaceuticals, Inc., commented,
"Over the course of his life in the public eye, Mr. Swann has proven himself
be a great leader both on and off the field. Transdel is extremely fortunate
strengthen its Board of Directors by adding an individual as experienced
accomplished as Mr. Swann. He is a tremendous addition to the Company's Board
especially given his extensive and diverse business background and business
affiliations. We are delighted to welcome him to the team and look forward
his contributions in growing Transdel and expanding the Company's business
added: "I am pleased and honored to be joining the Board of Directors of
Transdel Pharmaceuticals and look forward to contributing to the company's
future success. Transdel's transdermal delivery platform technology is truly
impressive. Given the growth of sports medicine, I am particularly excited
the company's lead drug, KetotransdelTM,
topical NSAID cream formulation for pain management and the unmet medical
that it will potentially fulfill."
Transdel Pharmaceuticals, Inc.
Pharmaceuticals, Inc. (OTCBB: TDLP - News) is a specialty pharmaceutical
developing non-invasive, topically delivered medications. The Company's
innovative patented proprietary Transdel cream formulation technology is
designed to facilitate the effective penetration of drugs through the tough
barrier to reach the target underlying tissues. In the case of Ketotransdel ,
the Transdel cream allows the active ingredient ketoprofen to reach the target
soft tissue and exert its well-known anti-inflammatory and analgesic effects.
The Company is also investigating other drug candidates and treatments for
transdermal delivery using the patented Transdel platform technology for
products in pain management and other therapeutic areas. For more information,
please visit http://www.transdelpharma.com.
statements which are not historical facts contained in this press release
forward-looking statements that involve certain risks and uncertainties
including but not limited to risks associated with the uncertainty of future
financial results, additional financing requirements, development of new
products, government approval processes, the impact of competitive products
pricing, technological changes, the effect of economic conditions and other
uncertainties detailed in the Company's filings with the Securities and Exchange
Pharmaceuticals, Inc.
Investor Relations Group
Colgate / Michael Crawford
Colontrelle / Janet Vasquez